Leading the way to safer medication
 Crosscheck  Recommender

Abemaciclib

Description

Abemaciclib is a potent and selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), and most active against Cyclin D1/CDK4 in enzymatic assays. Abemaciclib prevents retinoblastoma protein (Rb) phosphorylation, blocking cell cycle progression from the G1 to the S-phase of cell division, leading to suppression of tumour growth.

Medicine classification

ATC Code
Title
Class
L01EF03
Abemaciclib
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EF Cyclin-dependent kinase (CDK) inhibitors

Medicines

Drug
Countries

Australia Canada Singapore United States

Austria Cyprus France Lithuania Netherlands

Product monographs

Monograph
Type
Country
VERZENIOS Film-coated tablet
MPI, EU: SmPC